New anxiety drug shows promise in early brain study
Symptom relief
Recruiting now
This study tests whether a single dose of the experimental drug SYT-510 can reduce anxiety-related brain activity and behavior in 24 adults with generalized anxiety disorder. Participants will receive either the drug or a placebo, then switch after a washout period. The goal is t…
Phase: PHASE2 • Sponsor: Synendos Therapeutics AG • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC